MRG003+HX008

DRUG2 trials

Sponsors

Lepu Biopharma Co., Ltd.

Conditions

Advanced Solid TumorsRecurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Phase 1

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

RecruitingNCT05688605

Lepu Biopharma Co., Ltd.Advanced Solid Tumors

Start: 2022-06-30End: 2027-08-01Target: 18Updated: 2026-09-04

Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

CompletedNCT04868162

Lepu Biopharma Co., Ltd.Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Start: 2021-04-23End: 2024-07-26Updated: 2026-09-10

Related Papers

Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Journal of Clinical Oncology2026-08-25

Data from Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial

2026-06-17

Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck: A Multicenter, Phase IIa Trial.

2026-01-28

Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors.

Journal of Clinical Oncology2024-06-018 citations